Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Other Working Capital Changes of -$786.0 million for Q2 2026, down 254.05% year-over-year from $510.2 million in Q2 2025, and down 148.04% quarter-over-quarter from $1.6 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2012) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Other Working Capital Changes for 18 consecutive years, with -$786.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Working Capital Changes fell 254.05% year-over-year to -$786.0 million; the TTM figure through Jun 2026 stood at -$458.0 million (down 732.73% YoY), while the FY2025 annual figure was -$471.0 million, up 24.52% from the prior year.
- Other Working Capital Changes declined to -$786.0 million in Q2 2026 per CELG-RI's latest filing, from $1.6 billion in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $3.6 billion in Q3 2012 and bottomed at -$91.0 million in Q1 2012.
- Historically, Other Working Capital Changes has averaged $302.7 million across 4 years, with a median of -$2.0 million in 2010.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes jumped 185.27% — and 2024, when it tumbled 383.05%.
- Bristol Myers Squibb's Other Working Capital Changes stood at -$700.0 million in 2022, then surged by 59.57% to -$283.0 million in 2023, then plunged by 156.18% to -$725.0 million in 2024, then slumped by 47.31% to -$1.1 billion in 2025, then increased by 26.4% to -$786.0 million in 2026.
- Business Quant data shows CELG-RI's Other Working Capital Changes at -$786.0 million in Q2 2026, $1.6 billion in Q1 2026, and -$1.1 billion in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 3.62 Bn |
| Sep 30, 2012 | 3.62 Bn |
| Sep 30, 2012 | 3.62 Bn |
| Jun 30, 2012 | 43.00 Mn |
| Jun 30, 2012 | 43.00 Mn |
| Jun 30, 2012 | 43.00 Mn |
| Mar 31, 2012 | -91.00 Mn |
| Mar 31, 2012 | -91.00 Mn |
| Mar 31, 2012 | -91.00 Mn |
| Dec 31, 2011 | 4.00 Mn |
| Dec 31, 2011 | 4.00 Mn |
| Dec 31, 2011 | 4.00 Mn |
| Sep 30, 2011 | -21.00 Mn |
| Sep 30, 2011 | -21.00 Mn |
| Sep 30, 2011 | -21.00 Mn |
| Jun 30, 2011 | -41.00 Mn |
| Jun 30, 2011 | -41.00 Mn |
| Jun 30, 2011 | -41.00 Mn |
| Mar 31, 2011 | -57.00 Mn |
| Mar 31, 2011 | -57.00 Mn |